These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 2866786

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Trial of combination of guanethidine and oxprenolol in hypertension.
    Pearson RM, Bending MR, Bulpitt CJ, George CF, Hole DR, Williams FM, Breckenridge AM.
    Br Med J; 1976 Apr 17; 1(6015):933-6. PubMed ID: 773486
    [Abstract] [Full Text] [Related]

  • 23. Plasma concentration and antihypertensive effect of beta-receptor blockers.
    Hitzenberger G.
    Cardiology; 1979 Apr 17; 64 Suppl 1():14-9. PubMed ID: 42485
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Oxprenolol hydrochloride: a long-term study of efficacy, safety, and tolerability.
    Tarpley EL.
    Pharmacotherapy; 1982 Apr 17; 2(5):281-4. PubMed ID: 6820501
    [Abstract] [Full Text] [Related]

  • 30. Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate).
    Vukovich RA, Foley JE, Brown B, Willard DA, Buckley M, O'Kelly D, Fitzgerald D, Tormey W, Darragh A.
    Br J Clin Pharmacol; 1979 Apr 17; 7 Suppl 2(Suppl 2):167S-172S. PubMed ID: 37871
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.
    Motolese M, Muiesan G, Colombi A.
    Eur J Clin Pharmacol; 1975 Apr 17; 8(1):21-31. PubMed ID: 786673
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL, Krause-Steinrauf H, Goldman S, Clemson BS, Domanski MJ, Hager WD, Murray DR, Mann DL, Massie BM, McNamara DM, Oren R, Rogers WJ, Beta-Blocker Evaluation of Survival Trial (BEST) Investigators.
    J Card Fail; 2003 Aug 17; 9(4):266-77. PubMed ID: 13680547
    [Abstract] [Full Text] [Related]

  • 37. Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.
    Dahlöf B, Danielson M, Andersson O, Thulin T, Ohman P, Mörlin C, Boberg J, Karlberg BE, Jern S, Hansson L.
    Br J Clin Pharmacol; 1984 Dec 17; 18(6):831-6. PubMed ID: 6152175
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
    van Baak MA, Verstappen FT, Oosterhuis B.
    Eur J Clin Pharmacol; 1986 Dec 17; 30(4):399-406. PubMed ID: 3743615
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.